May 8, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combina

May 9, 2026 -- Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially received Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) for the proposed indication of advanced thoracic midline (NUT) carcinoma in patients who have failed prior chemotherapy. This milestone progress brings new targeted therapy hope to NUT carcinoma patients, a disease with extremely high ma

12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety pro durable structural and functional benefits in patients with X-linked retinoschisis Three-year data from Phase 1/2 trial confirm durable efficacy and tolerability of ATSN-101 in patients with Leber congenital amaurosis type 1 Atsena is advancing ATSN-201 and ATSN-101 into pivotal clinical trials in 2026 May 07, 2026 -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-cha

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy. This application is part of the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which is

6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first clinical site in the ZIMA-101 Phase 1 trial has now been activated. This marks the transition of the study from clinical preparation to active trial execution of the ZIMA-101 study. The first activated clinical site is The Christie NHS Foundation Trust in the United Kingdom, where Profess

Fast Track Designation granted for RPTR-1-201, a T cell receptor bispecific, in triple-negative breast cancer Designation underscores the potential of RPTR-1-201 to address a serious disease with high unmet needs May 7, 2026 -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RPTR-1-201 for the trea

May 06, 2026 -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proli

May 07, 2026 -- SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases. This partnership, focused on viral vector programs, underscores SK pharmteco’s commitment to the rare disease sector and its role as a key technical partner for leading research institutions. As a subcontractor to the NIH, SK pharmteco is working with Axle Informatics, the NIH’s primary contractor,

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Angelini Pharma is putting up $4.1 billion in a play for Catalyst Pharmaceuticals, scooping up three rare disease drugs that will allow the Italian company to enter the U.S. market. Angelini believes the buyout will establish the company as “a relevant global player in neurological rare diseases,” CEO Sergio Marullo di Condojanni said in a Thursday announcement. Created in 2002,

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access May 7, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatm